Drug intelligence / Profile preview

PRN-002-01

Development stage: Unknown
Lead developer: Proniras
Modality: Small Molecules
Administration: Oral

Overview

PRN-002-01 is an orally administered small molecule modulator of AMPA and kainate receptors currently in Phase 1 clinical development by Proniras. The drug is designed to target ionotropic glutamate receptors to treat a variety of central nervous system (CNS) disorders. By modulating excitatory neurotransmission mediated by AMPA and kainate receptors, PRN-002-01 aims to provide therapeutic benefits in conditions where glutamatergic signaling is imbalanced. It is part of a broader pipeline of glutamate receptor modulators developed by Proniras for neurological and psychiatric indications.

Targets

Kainate-type ionotropic glutamate receptorAMPAR (AMPA receptor)

Beyond the preview

Go deeper on PRN-002-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRN-002-01.

Explore the full profile